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Epidemiologic studies over the past several
decades have suggested that even slightly ele-
vated lead levels during early childhood can
produce cognitive impairments and behavioral
problems that endure long past the period of
exposure (e.g., Bellinger et al. 1984, 1992;
Dietrich et al. 1993; Fergusson et al. 1993;
Needleman et al. 1990). In fact, Canﬁeld et al.
(2003) recently reported a signiﬁcant inverse
correlation between IQ and blood lead levels
across the range of 2–10 µg/dL, suggesting
adverse effects at lead levels lower than previ-
ously recognized. Importantly, studies using
animal models have also demonstrated lasting
cognitive and affective changes in animals
exposed to lead early in life (e.g., Garavan et al.
2000; Levin and Bowman 1986; Morgan et al.
2001; Rice 1992; Stangle et al. 2003). These
latter ﬁndings provide important evidence that
early lead exposure can, in fact, cause these
lasting deﬁcits, an inference that has remained
tentative in human studies because of the
correlational nature of the data and frequent
confounding of lead exposure and other risk
factors for impaired cognitive and affective
development.
Several studies have shown that interven-
tions focusing on abatement and education
produce only moderate reductions in lead lev-
els over prolonged periods of follow-up. For
example, Roberts et al. (2001) showed that
blood lead levels of 25–29 µg/dL required
24 months to decline to < 10 µg/dL (the cur-
rent level of concern for children), although
all families received education, counseling,
lead hazard identification, and relocation
when possible. These data underscore the
need for therapeutic chelating agents to reduce
body lead levels more rapidly than can be
achieved through environmental efforts alone.
Therapeutic chelation treatment has been
used for decades to treat childhood lead
poisoning (for reviews, see Graziano 1986;
Graziano et al. 1985). According to current
Centers for Disease Control and Prevention
(CDC) guidelines (2002), chelation with
Versenate (CaNa2EDTA) is indicated for chil-
dren with blood lead levels ≥ 45 µg/dL, but
more ambiguity exists regarding optimal
therapeutic intervention for children with
moderately elevated lead levels (25–45 µg/dL).
The use of the oral chelating agent succimer
has increased over the last several years because
of its benefits over Versenate. Succimer is
orally effective and is more specific for lead
than is Versenate, thereby avoiding the diure-
sis of essential elements (e.g., calcium and
zinc; Bentur et al. 1987; Chisolm 2000; Flora
et al. 1995; Graziano et al. 1988; Kostial
et al. 1999; Smith et al. 2000a; Thomas and
Chisolm 1986).
Most studies demonstrating the effective-
ness of succimer (and Versenate) in reducing
tissue lead levels have assessed efficacy soon
after the completion of treatment. However,
recent clinical and nonhuman primate studies
have suggested that succimer may be no more
effective in reducing body lead levels than the
simple cessation of lead exposure, when treat-
ment efﬁcacy is evaluated over longer periods
of time after chelation (Cremin et al. 1999;
Liu et al. 2002; O’Connor and Rich 1999;
Rogan et al. 2001; Ruff et al. 1993; Smith
et al. 2000b). Moreover, the one clinical trial
of succimer treatment that has included cog-
nitive outcomes [Treatment of Lead-Exposed
Children (TLC) Trial Group 2000] was
unable to detect a benefit of succimer treat-
ment (relative to placebo) on cognitive func-
tioning (Rogan et al. 2001). It is possible that
the duration of succimer treatment in the
TLC study was insufficient to significantly
lower brain lead levels, despite the lowering of
blood lead levels. This possibility is based on
the evidence from animal studies that suc-
cimer-induced reductions in brain lead lag
behind reductions in blood lead (Cremin et al.
1999; Smith et al. 1998), and that extended
succimer treatment can continue to lower
brain lead levels without continued reductions
in blood lead (Smith et al. 1998).
In clinical practice, blood lead levels are
used to determine the duration of chelation
therapy (i.e., number of regimens) and assess
its efﬁcacy. Yet, as noted above, recent animal
studies indicate that chelation-induced reduc-
tions in brain lead significantly lag behind
changes in blood lead. As a result, in the short
term, changes in blood lead may greatly over-
estimate the efﬁcacy of chelation in reducing
brain lead (Cremin et al. 1999; Smith et al.
1998). It follows that extending the duration
of succimer treatment will significantly
increase the efﬁcacy of the drug in removing
brain lead and, ideally, lessen the resulting
cognitive dysfunction. For these reasons, there
is a pressing need to determine the efﬁcacy of
varying durations of succimer treatment on
blood and brain lead levels, as well as the more
general issue of the correspondence between
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Although many studies have demonstrated the efficacy of succimer chelation in reducing blood
and brain lead levels, the relative efficacy of the drug in the two tissues is less well understood.
This issue is important because blood lead levels after chelation are used clinically to estimate
reductions in the brain, the most critical organ in considering lead-induced neurotoxicity. The
present study was designed to further investigate this issue, using multiple chelation regimens.
Long-Evans rats were exposed to one of three lead exposure regimens from birth until postnatal
day 40, followed by treatment with succimer (one or two 3-week regimens) or vehicle. The results
indicated that one succimer regimen was significantly superior to vehicle treatment in lowering
lead levels in both blood and brain across the entire 8-week follow-up period. Similarly, a second
succimer regimen offered signiﬁcant additional beneﬁt relative to one regimen for both blood and
brain across the 4-week follow-up period. However, several findings revealed that succimer-
induced reductions in brain lead lagged behind reductions in blood lead and were generally
smaller in magnitude. Furthermore, a rebound was detected in blood, but not brain, lead levels
after both succimer regimens. Given the results of this study, we urge caution in using blood lead
as a surrogate for brain lead levels, particularly during and immediately after chelation treatment
when reductions in blood lead levels overestimate reductions in brain lead levels. The present
results suggest that, in clinical use, succimer treatment may need to extend beyond the point at
which blood lead levels have dropped to an “acceptable” target value in order to effectively reduce
brain lead levels and minimize neurotoxicity. Key words: chelation, dimercaptosuccinic acid, lead
exposure, lead poisoning, neurotoxicity, succimer. Environ Health Perspect 112:302–308 (2004).
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chelation therapy.
In the present study we used a rodent
model of childhood lead exposure to system-
atically investigate a) the efﬁcacy of single ver-
sus repeated succimer treatment regimens for
reducing blood and brain levels, b) the extent
to which blood lead can serve as a proxy for
brain lead during and after chelation, and
c) whether rebounds in blood and brain lead
levels occur after chelation therapy, in the
absence of environmental reexposure.
Materials and Methods
Experimental design. The present study was a
3 × 3 factorial design, involving three levels of
lead exposure and three levels of chelation
therapy (vehicle, one 3-week succimer regi-
men, two 3-week succimer regimens). Animals
were followed for a total of 11 weeks after
cessation of lead exposure, corresponding to
8 weeks after the ﬁrst chelation regimen ended
and 4 weeks after the second regimen ended.
As depicted in Figure 1, animals were sacri-
ficed at various time points throughout the
study to assess the efficacy of succimer in
reducing blood and brain lead levels. This
lengthy follow-up period allowed assessment
of succimer efﬁcacy in both blood and brain
across various postchelation time periods,
as well as an assessment of the potential
“rebounding” of blood and brain lead levels
after cessation of chelation.
Animals. Nulliparous Long-Evans rats
(Harlan Sprague Dawley, Indianapolis, IN)
were housed in animal facilities accredited
by the Association for the Assessment and
Accreditation for Laboratory Animal Care,
with a 12:12-hr light:dark cycle. Food (Pro-
Lab RMH 1000; Nutrition International
LLC, Brentwood, MO) and water were avail-
able ad libitum. Rats were mated at approxi-
mately 10 weeks of age. Pregnancy was
determined by the presence of a sperm plug
and subsequent weighing of the females at
approximately 5-day intervals. Dams were
maintained on tap water and laboratory chow
during gestation.
Lead exposure. Lead was administered
from birth until postnatal day (PND) 40.
Until weaning on PND21, the pups received
lead via nursing from lead-exposed dams,
whereas from PND21 through PND40, the
pups directly consumed lead from their water
supply. At birth, each dam was randomly
assigned to a lead exposure condition. All dams
received lead via drinking water (600 µg/mL
lead as lead acetate) during PND1–18, fol-
lowed by daily oral administration of an equiv-
alent lead dose to the dams via eye dropper
until weaning on PND21. After weaning, the
lead exposure diverged into two groups as fol-
lows: a) 20 µg/mL lead in the drinking water
during PND21–28, followed by 30 µg/mL
during PND29–40, or b) 40 µg/mL lead in the
drinking water during PND21–28, followed by
60 µg/mL during PND29–40. Lead exposure
in all animals was terminated at PND40.
The decision to give all dams the same
lead dose during lactation (PND1–21) was
based on prior studies in our laboratory show-
ing that pup blood lead levels remain rela-
tively low and constant across a wide range of
maternal intakes (15–25 µg/dL) (Garavan
et al. 2000; Morgan et al. 2001) and do not
increase until very large doses are used that
produce maternal toxicity (unpublished data).
The selection of lead doses after weaning was
also based on prior studies in our lab (unpub-
lished data). The lower-dose regimen pro-
duces relatively consistent, low blood lead
levels, whereas the higher-dose regimen pro-
duces a wider range of blood lead levels.
These two doses together therefore allowed us
to examine low, moderate, and high exposure
in the pups.
Twenty-four hours after birth, the litters
were culled to 10 pups. Within each lead treat-
ment condition, 10 subgroups were deﬁned by
the ﬁve sacriﬁce dates and three succimer treat-
ment conditions (vehicle, one succimer regi-
men, two succimer regimens; see Figure 1).
When possible, one pup per litter was assigned
to each of these 10 subgroups, with the goal of
providing littermate comparisons for these
10 conditions, and to avoid having more than
one animal per litter in a given subgroup.
Chelation. Succimer (Chemet; Sanofi-
Synthelabo Inc., New York, NY) was adminis-
tered via oral gavage at a dose of 50 mg/kg/day
for 1 week followed by 25 mg/kg/day for an
additional 2 weeks, for a total treatment dura-
tion of 3 weeks per regimen. Succimer was dis-
solved in apple juice and administered within
15 min of mixing. The vehicle groups received
equivolume apple juice carrier, also by gavage.
The daily dose of succimer or vehicle was
divided and administered as two equal doses
given 10–12 hr apart.
Sample collection and analysis. Animals
were sacriﬁced at ﬁve time points throughout
the study (Figure 1) to assess the efﬁcacy of the
various treatments in lowering blood and brain
lead levels, as follows: a) One animal per litter
was sacrificed at PND41, immediately after
cessation of lead exposure, and immediately
before the start of chelation. Sacrifice at this
time point provided a representative measure
of the tissue lead levels for each litter. b) On
PND62, immediately after the ﬁrst round of
chelation treatment, both succimer- and vehi-
cle-treated animals from each lead exposure
condition were sacriﬁced to assess the immedi-
ate efficacy of one chelation regimen. c) An
additional group of rats that received one
round of succimer treatment were sacriﬁced at
PND69, 1 week after treatment ended and
immediately before the second round of chela-
tion treatment began, to examine whether a
rebound in blood and/or brain lead levels
occurred after cessation of succimer treatment.
d) Rats from each chelation treatment group
(vehicle, one succimer regimen, two succimer
regimens) were sacriﬁced at PND90, immedi-
ately after the second round of chelation (and
4 weeks after the first round of chelation
ended). Sacriﬁce at this time served a dual pur-
pose to examine the long-term effects of one
round of succimer treatment and the added
benefit of a second round of succimer treat-
ment compared with one round of treatment.
e) Finally, animals from each of the three
chelation conditions were sacrificed at
PND118, 8 weeks after the ﬁrst chelation regi-
men and 4 weeks after the second regimen.
Sacriﬁce at this time point also served a dual
function: to assess the long-term efﬁcacy of one
and two succimer regimes relative to vehicle
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Figure 1. Study design. Lead exposure occurred from PND0 through PND40, followed by either one 3-week
regimen of succimer, two 3-week regimens of succimer, or vehicle treatment. Arrows represent days at
which rats from each lead exposure group were sacriﬁced and blood and brain lead levels analyzed.
Lead exposure
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Age (days)treatment and relative to each other, and
whether a rebounding occurred in blood or
brain levels after the second chelation regimen.
At the time of sacriﬁce, a 2- to 3-mL sam-
ple of whole blood was collected into a poly-
propylene syringe via cardiac puncture from
surgically exposed hearts of anesthetized
animals and deposited into Vacutainers speci-
fied for trace metal (no. 367734, Becton
Dickson, Research Triangle Park, NC).
Animals were given a sodium pentobarbital
overdose (50 mg/kg) and exsanguinated.
Whole brain was removed using acid-washed
stainless-steel dissecting tools, rinsed with
Milli-Q water, and deposited into polypropy-
lene storage containers. All tissue sampling
was conducted using trace-metal–clean proce-
dures. Dissecting instruments (stainless steel)
were cleaned before each dissection and rinsed
frequently within a dissection procedure to
avoid contamination from nonbrain tissues.
All samples were stored frozen.
Lead concentrations were measured in
whole blood and brain tissue. Blood lead levels
were determined using graphite furnace atomic
absorption spectroscopy at the Wisconsin State
Laboratory of Hygiene (WSLH; Madison,
WI). The WSLH administers the Nationwide
Blood Lead Proficiency Testing Program in
cooperation with the Centers for Disease
Control and Prevention and the Maternal and
Child Health Bureau. Brain lead levels were
measured at the University of California,
Santa Cruz, using a Finnegan-element induc-
tively coupled plasma (ICP)/high-resolution
mass spectrometer (MS) in multi-isotope
counting mode, measuring masses 208Pb and
209Bi, with 209Bi used as an internal standard
(Smith et al. 2000a, 2000b; Woolard et al.
1998). External standardization was via a cer-
tiﬁed lead standard that had been isotopically
characterized independently via thermal ion-
ization MS. National Institute of Standards
and Technology (Gaithersburg, MD) Standard
Reference Materials 955A (blood) and 1577
(bovine liver) were used to evaluate procedural
accuracy. This ICP/MS methodology has been
demonstrated to yield a measurement precision
of < ± 0.5% for sample lead concentrations of
≥ 0.05 ppb (Woolard et al. 1998). The analytic
detection limit was 0.01 ppb.
Statistical analysis. All statistical analyses
were conducted using SAS 8.2 (SAS Institute,
Inc., Cary, NC). The present data contained
correlated observations due to the use of two
observations from each animal (blood and
brain) and due to the use of multiple animals
per litter. Therefore, a repeated-measures analy-
sis of variance model (PROC MIXED; Littell
et al. 1996) was used. To analyze the data for
both tissues in a single analysis, blood and brain
lead concentration data were first converted
to comparable units of parts per billion (i.e.,
nanograms per milliliter and nanograms
per gram, respectively). However, box plots
indicated that the scale and skewness were
larger in the brain samples than in the blood
samples. A natural log transformation was
applied to normalize the residuals and reduce
the scale of the random effects. Taking a log
transformation is often successful when the
effects in the model are proportional rather
than additive.
The estimated least-squares means pro-
duced in the analysis of log-transformed
data are expressed as geometric means after 
back-transforming to the original units.
Exponentiation of the difference in least-
squares means on the analysis scale is equiva-
lent to the ratio of geometric means on the
original scale. Therefore, the usual tests of
effects involving differences in means on the
analysis scale (i.e., succimer minus vehicle) are
actually assessing proportional, or relative,
changes in the original units (i.e., succimer/
vehicle). Figures are presented in the original
scale for ease of interpretation. Standard
errors for means are not included on the ﬁg-
ures because the appropriate standard error of
a difference in means cannot be derived
directly from the individual mean standard
errors because of the covariance terms, which
vary by the particular groups being compared.
The “one succimer regimen” analysis
investigated vehicle versus one cycle of suc-
cimer treatment at three time points: PNDs
62, 90, and 118. The “two succimer regi-
mens” analysis investigated the efficacy of
vehicle, one cycle of succimer, and two cycles
of succimer at the two time points after the
second chelation regimen: PNDs 90 and 118.
The initial models were constructed contain-
ing the main effects of tissue type (blood or
brain), lead exposure group, succimer treat-
ment (vehicle, one cycle, or two cycles), and
time (age at sacriﬁce). Preliminary analysis of
the animals sacriﬁced immediately after cessa-
tion of lead exposure (PND41), before chela-
tion, confirmed that the higher exposure
regimen produced a much wider range of
blood lead levels (range, 25–160 µg/dL) than
did the lower exposure regimen (range, 20–30
µg/dL). Therefore, for the two analyses of the
chelation treatment effects, a three-level lead
exposure variable was created, in which each
animal’s lead exposure designation was based
on the blood lead level of the littermate that
was sacriﬁced at PND41. This three-level des-
ignation explained much more of the varia-
tion in the data than did a two-level
designation, based on the Akaike Information
Criterion (Akaike 1974; Bozdogan 1987;
Wolfinger 1993). The initial models also
included all relevant two-, three-, and four-
way interactions involving the main effects.
Each model was reduced by removing the
least signiﬁcant higher-order term ﬁrst, reeval-
uating the model, and repeating the process
until all effects were either significant at
approximately the 5% level or included in a
higher-order term that was signiﬁcant.
Results
Data. Blood and brain levels were collected
from 140 animals, from 25 litters. However,
only data from a slightly smaller number of
samples (136 blood samples and 131 brain
samples) were available for statistical analyses
because of collection and/or analytic problems.
In addition, in the course of statistical analysis,
it was discovered that ﬁve animals had unusu-
ally high lead levels in either blood (n = 1) or
brain (n = 4), without correspondingly high
values in the other sample from the animal.
These values were orders of magnitude differ-
ent from other animals receiving the same ini-
tial exposure, treatment, and follow-up time,
suggesting an analytic problem. One possible
explanation for the four high brain measure-
ments is that the samples were contaminated
during collection and/or processing for analy-
sis, possibly by the inclusion of a small skull
fragment. These five observations were
excluded from the analyses presented below.
As noted above, three lead groups were
designated for analysis based on the blood lead
level of the littermate sacrificed on PND41.
The resulting low, medium, and high lead
exposure groups had average (± SD) blood
lead levels of 24.4 (± 3.2), 49.5 (± 10.8), and
131.3 (± 26.0) µg/dL, respectively. Average
(± SD) brain lead levels for the three groups
were 1,825 (± 374), 2,867 (± 247), and 6,781
(± 1,863) ng/g dry weight, respectively.
Efficacy of a single succimer treatment
regimen. For each of the three time points
examined (immediately after the ﬁrst chelation
regimen at PND62, as well as PND90 and
PND118), the animals treated with succimer
had significantly lower lead levels in both
blood and brain than did their vehicle-treated
counterparts (all p < 0.0001). However, as
indicated by a significant interaction among
treatment, tissue, and time [F(2,156) = 6.68,
p = 0.002], treatment efﬁcacy varied as a func-
tion of both tissue type and time after chela-
tion (Figure 2). At the end of the ﬁrst chelation
(PND62), the reduction in brain lead pro-
duced by succimer treatment (compared with
the vehicle-treated animals, i.e., succimer/vehi-
cle) was signiﬁcantly smaller than that seen in
blood (p = 0.0006). Across the following
8 weeks of the study, brain lead continued to
drop in both the succimer- and vehicle-treated
animals, with the relative difference between
the two groups remaining relatively constant.
In contrast, blood lead levels in the succimer-
treated group increased significantly (i.e.,
rebounded) over the 4 weeks after chelation,
whereas blood lead levels in the vehicle group
continued to decrease. Between PND90 and
PND118 (4 and 8 weeks after chelation),
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succimer-treated animals (p = 0.9), at a level
that was signiﬁcantly lower than their vehicle-
treated counterparts. These findings demon-
strate that although succimer treatment was
highly effective in removing lead from both tis-
sues, the reduction in brain lead levels lagged
significantly behind the reduction in blood
lead levels.
A signiﬁcant interaction was found between
treatment and lead exposure group [F(2, 159)
= 5.65, p = 0.004]. Although succimer treat-
ment was significantly more effective than
vehicle in removing lead from all three lead
exposure groups (p < 0.0001), the magnitude
of the succimer effect relative to vehicle varied
by lead exposure group (Figure 3). The suc-
cimer effect relative to vehicle was largest in
the low lead group and decreased with increas-
ing lead exposure. However, as shown in
Figure 3, the absolute amount of lead
removed by succimer was larger in the high-
lead group than in the two lower groups.
Rebound analysis after one cycle of
succimer. The “rebound” analysis included
data from the day immediately after chelation
(PND62), as well as 1 and 4 weeks later
(PND69 and PND90). There was a signiﬁcant
tissue type by time interaction (p < 0.0001).
Averaged over lead exposure groups, blood lead
levels exhibited a rebound 1 week after the ces-
sation of treatment (p < 0.0001), but brain lead
levels did not (p = 0.80; Figure 4). Further,
whereas both blood and brain showed a
decline in average lead levels from PND69 to
PND90 (1–4 weeks after chelation), blood
lead values at 4 weeks after chelation were still
significantly higher than those seen immedi-
ately after chelation ended, as presented above.
Thus, a rebound in lead levels was detected in
blood but not in brain.
Analysis assessing the added benefit of a
second cycle of succimer treatment. This analy-
sis included data from PND90 and PND118,
corresponding to the day immediately after
the second chelation regimen ended and
4 weeks later. The analysis was performed on
88 brain specimens and 97 blood specimens,
contributed by 101 animals. As depicted in
Figure 5, the animals that received two cycles
of succimer had signiﬁcantly less lead in both
brain and blood than did animals that received
either one succimer regimen or vehicle treat-
ment (all p < 0.008). Therefore, two cycles of
succimer offered a significant added benefit
relative to one cycle throughout the time
period examined.
However, treatment efficacy varied as a
function of tissue type, time, and lead expo-
sure, as indicated by two borderline three-way
interactions involving treatment, as well as
several signiﬁcant underlying two-way interac-
tions. A borderline interaction among treat-
ment, tissue type, and time [F(2, 137) = 2.93,
p = 0.06] reﬂected the fact that the magnitude
of the added benefit of the second succimer
regimen varied as a function of both tissue type
and time since the second regimen ended.
Immediately after the second chelation, the
benefit of one cycle of succimer (relative to
vehicle) and the added beneﬁt of the second
cycle (relative to only one cycle) were of simi-
lar magnitude in blood and brain tissue
(Figure 5). However, 4 weeks later (PND118),
the beneﬁt of the second regimen (relative to
vehicle) was signiﬁcantly greater for brain than
for blood (p = 0.002). This pattern of ﬁndings
reﬂects the fact that during the ﬁnal 4 weeks of
the study, brain lead continued to decline in all
treatment groups, whereas blood lead levels of
the one-cycle succimer group remained rela-
tively constant, and that of the two-cycle suc-
cimer group significantly increased (i.e.,
rebounded; p = 0.05).
A separate analysis was conducted on the
blood samples from the animals receiving two
cycles of succimer, based on the evidence
(above) that the rebound occurred only in the
blood, and because this approach decreased the
residual error (the brain samples are more vari-
able than the blood samples). This analysis
showed that the average lead level in the blood
was higher 4 weeks after the second chelation
than immediately after cessation of the second
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Figure 2. The efficacy of one regimen of succimer
(relative to vehicle treatment) in lowering blood and
brain lead levels, assessed at various times after
chelation ended on PND61. Tissue lead concentra-
tions are expressed as parts per billion (ppb; for
blood and brain this is equivalent to nanograms of
lead per milliliter and nanograms of lead per gram
dry weight, respectively). For comparison, 10 ppb
blood lead equals 1 µg/dL.
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Figure 3. The efﬁcacy of one regimen of succimer
(vs. vehicle treatment) in lowering tissue lead lev-
els (blood and brain levels combined), as a function
of lead exposure, when assessed immediately after
the first succimer regimen (PND62; see text for
details). 
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Figure 4. Levels of (A) brain and (B) blood lead
across the 4 weeks after completion of the first
succimer regimen. 
1,000
800
600
400
200
0
L
e
a
d
 
(
n
g
/
g
)
Weeks postchelation
10
8
6
4
2
0
● ●
●
●
●
●
L
e
a
d
 
(
µ
g
/
d
L
)
(PND 62) (PND 90)
01234
01234
A
B
Figure 5. Additional beneﬁt of the second regimen
of succimer treatment (vs. one regimen and vehicle
treatments) in reducing blood and brain lead levels,
as a function of time since the second regimen
ended (see text for details). 
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Succimer two cycleschelation for the medium (p = 0.05) and high
(p = 0.0003) exposure groups. For the low lead
exposure group, the lead levels were very low at
both time points and there was no difference
in the average lead levels at the two time
points. Thus, a significant rebound in blood
lead levels, but not brain lead, occurred after
the second chelation, similar to the pattern
after the ﬁrst succimer regimen.
A signiﬁcant two-way interaction between
treatment and lead exposure group was found
[F(4, 144) = 5.77, p = 0.0002], as well as a
borderline three-way interaction among treat-
ment, lead exposure, and time [F(4, 137) =
2.93, p = 0.056]. When assessed immediately
after the second regimen (PND90), all three
exposure groups derived a signiﬁcant beneﬁt
of the second regimen (vs. one regimen; all
p < 0.007), although there were subtle differ-
ences in the reduction in tissue lead relative to
vehicle as a function of lead exposure. When
assessed 4 weeks later (PND118), the beneﬁt
of a second chelation regimen (vs. one regi-
men) was still apparent in the low and
medium groups but not the high exposure
group (Figure 6). This finding appears to
reﬂect primarily the rebounding of blood lead
over the 4 weeks after the second chelation,
which was greatest for the high-lead group.
Discussion
The results of this study provide important
insights into the efficacy of succimer for the
treatment of lead poisoning. First, both suc-
cimer regimens were signiﬁcantly more effec-
tive than vehicle treatment in lowering lead
levels in both blood and brain, although the
reductions in brain lead temporally lagged
behind reductions in blood lead over both
treatments. In addition, a rebounding of lead
levels was seen in blood but not brain after
cessation of each chelation regimen. Each of
these conclusions is discussed below.
Effectiveness of succimer treatment: blood
versus brain. One regimen was significantly
superior to vehicle treatment in lowering lead
levels in both blood and brain across the entire
8-week follow-up period. Similarly, a second
succimer regimen offered significant addi-
tional beneﬁt relative to one regimen for both
tissues across the 4-week follow-up period.
However, several findings revealed that suc-
cimer-induced reductions in brain lead lagged
behind treatment reductions in blood lead.
First, when assessed immediately after the ﬁrst
round of chelation, the succimer-induced
reduction in lead levels (relative to vehicle lev-
els) was greater for blood than for brain. The
ﬁnding that a single chelation regimen is less
effective in reducing brain lead than blood
lead has been observed in other studies using
either Versenate or succimer (Cremin et al.
1999; Flora et al. 1995; Seaton et al. 1999;
Smith et al. 1998). This effect likely reflects
two factors: First, lead in the blood is more
accessible for chelation than is lead in the
brain, based on the indications that chelators
remove lead primarily by forming a soluble
lead chelate that can be more readily elimi-
nated via urinary or fecal routes, and by creat-
ing increased concentration gradients that
favor lead efﬂux from tissues into the circula-
tion. A second contributing factor is the inher-
ently different toxicokinetics of lead in blood
and brain. This phenomenon is best illustrated
by the relatively slow rate of lead reduction in
brain compared with blood of vehicle-treated
animals over the entire study period (Figure 2).
It follows, therefore, that the most effective
means of reducing lead levels in well-perfused
tissues exhibiting slow lead toxicokinetics
(brain), as well as poorly perfused tissues (e.g.,
the skeleton), is to maximize the lead concen-
tration gradient between these tissues and
blood for prolonged periods of time, thereby
favoring continued efflux of lead into the
circulation and elimination via urinary or
fecal routes.
When assessed at the end of the study
(PND118), the added benefit of the second
succimer regimen was more apparent for brain
lead levels than for blood lead levels. This pat-
tern also reﬂects the lag of brain lead reduction
(relative to blood) and the different lead toxi-
cokinetics of the two tissues. Because of the
slower rate of lead efﬂux from brain, lead levels
in this tissue were still elevated after the ﬁrst
regimen, whereas at this time blood lead levels
were very low and appeared to have reached an
asymptote. This apparent “ﬂoor” effect may be
the result of both a lower amount of chelatable
lead in blood and also blood lead toxicokinetics
(i.e., the relative rates of lead inﬂux to blood
from other tissues vs. the rate of efﬂux of lead
out of the circulation). Nevertheless, the ﬁnd-
ing that the second succimer regimen offered a
significant benefit in terms of reducing lead
levels in both blood and brain, at all exposure
intensities, is important because it indicates
that multiple chelation regimens continue to
lower brain lead levels, even at time points
when blood lead levels have appeared to “stabi-
lize” at a relatively low level. This observation
may be particularly important in the clinical
management of lead-poisoned children,
because it suggests that chelation treatment
may need to continue past the point at which
blood lead levels have reached an acceptably
low level, to achieve the maximal beneﬁt of the
treatment on brain lead levels, the primary goal
in lessening cognitive dysfunction.
Experimental studies in rodents and non-
human primates have yielded different results
concerning the efﬁcacy of succimer in reducing
lead in blood and brain. For example, Cory-
Slechta (1988), Flora et al. (1995), and Smith
et al. (1998) found that succimer signiﬁcantly
reduced both blood and brain lead levels in
rats. In contrast, a recent study in adult rhesus
monkeys found that succimer treatment meas-
urably reduced lead levels in blood but not
brain (Cremin et al. 1999). The recent studies
of succimer efficacy that included cognitive
assessments have also yielded inconsistencies
between species. Cognitive functioning was
not improved by succimer treatment in the
recent TLC clinical trials with children (Rogan
et al. 2001), whereas a signiﬁcant beneﬁt was
seen in recent studies with juvenile nonhuman
primate (Laughlin and Smith 2001; Laughlin
et al. 1999) and rat (Stangle et al. 2003) mod-
els of childhood lead exposure. The basis for
these inconsistencies between the rodent and
primate studies is not clear. However, two pos-
sibly important factors may be differences in
the lead exposure history of the subjects and/or
the functional duration of succimer treatment
(i.e., considering species differences in meta-
bolic rate). In particular, the results presented
here suggest that chelation treatment may not
have been of sufﬁcient duration in the human
and adult nonhuman primate studies to be
maximally effective in terms of reducing brain
lead levels.
Rebounding of lead levels after cessation of
chelation. We observed a signiﬁcant increase
(i.e., rebound) in blood lead levels but not
brain lead levels after both chelation regimens.
Rebounds in blood lead levels have been
reported after succimer treatment in non-
human primates (Smith et al. 2000b) and in
humans (Chisolm 2000; Graziano et al. 1985,
1988, 1992; Liebelt et al. 1994; Liu et al.
2002; Rogan et al. 2001). The consistency of
this rebound across laboratory (rodent and
primate) and clinical studies, including the
recent TLC study (Rogan et al. 2001),
demonstrate the importance of mobilized lead
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Figure 6. Additional beneﬁt of the second regimen
of succimer treatment (vs. one regimen and vehicle
treatments) in reducing tissue lead (blood and
brain combined), as a function of both the intensity
of prior lead exposure and time since the second
regimen ended (see text for details).
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as a predominant contributor to the rebound,
although reexposure to environmental lead
may also have occurred in the clinical studies.
The rebound in blood lead levels observed
here was not accompanied by a rebound in
brain lead levels after either one or two cycles
of succimer. The most likely explanation for
this is that the lead concentration gradient
between the blood and the brain postchelation
continued to favor brain lead efﬂux, because of
the slower reduction in brain lead levels relative
to blood lead levels. Nonetheless, it is likely
that the rebound in blood lead levels may have
reduced the rate of decline in brain lead
levels by reducing the concentration gradient
between blood and brain lead postchelation.
However, the larger within-group variance in
brain lead levels compared with blood lead lev-
els may have limited our ability to detect a
rebound in brain lead levels.
Clinical implications. In clinical practice,
decisions about chelation therapy are based on
blood lead levels. However, the present results
raise concerns about the adequacy of this
practice. As noted above, the present ﬁndings
demonstrate that after cessation of lead expo-
sure, reductions in brain lead levels lag behind
blood lead reductions in both nonchelated
and chelated animals, though particularly in
the latter. This finding is consistent with
results from earlier rodent and nonhuman pri-
mate studies (Cremin et al. 1999; Smith et al.
1998). An obvious consequence of this lag is
that brain lead levels are likely to still be ele-
vated at times that blood leads have reached
some lower value that may no longer indicate
the need for additional chelation. For exam-
ple, consider the data for the low and medium
exposure groups in the present study (the
range of blood lead levels that approximates
those seen clinically): Immediately after the
ﬁrst chelation treatment (PND62), all 15 ani-
mals in these two exposure groups had blood
lead levels at or below the analytic detection
limit (5 µg/dL), whereas their brain lead levels
remained quite elevated and to varying degrees
(i.e., mean, 423 ± 197; range, 200–941 ng/g,
compared with expected brain lead levels in
non–lead-exposed animals of ~50 ng/g dry
weight). These ﬁndings, as a group, point to
serious limitations in using blood lead level as
an indicator of brain lead when making deci-
sions about the need for chelation therapy,
particularly after a single chelation regimen
when decisions are being made about the need
for additional regimens.
Our findings have implications for the
clinical use of succimer and its potential to
ameliorate lead-induced cognitive dysfunction.
Some studies have suggested that declines
in blood lead levels in children are associated
with improved cognitive outcomes (Ruff et al.
1993; Tong et al. 1998). Given the present
finding that succimer treatment reduced
blood and brain lead levels signiﬁcantly faster
than did vehicle treatment (i.e., simple abate-
ment), it follows that therapeutic use of the
drug would reduce the amount of time that
brain lead levels are elevated. As a result, the
severity of the cognitive dysfunction should
be reduced, based on evidence that lead inter-
feres with brain development (e.g., Wilson
et al. 2000). However, the TLC study, which
is the only clinical study to date examining
neuropsychologic functioning in lead-exposed
subjects receiving succimer (Rogan et al. 2001),
was unable to detect a significant benefit of
succimer in terms of cognitive outcomes (rela-
tive to placebo), despite a signiﬁcant lowering
of blood lead levels in the treated subjects. The
present ﬁndings suggest that although the treat-
ment regimen used in the TLC study was sufﬁ-
cient to reduce blood lead levels below the level
of concern in that study (15 µg/dL), it is likely
that brain lead levels remained elevated after the
cessation of treatment, because of the substantial
lag in reduction of brain lead compared with
blood lead levels. In the present study, the aver-
age blood lead level before receiving a second
course of succimer treatment was < 15 µg/dL
for all exposure groups; yet this second regimen
produced a very signiﬁcant further reduction in
lead levels in both blood and brain for all
groups. Thus, the present results suggest that
treatment regimens may need to extend beyond
the point at which blood lead levels have
dropped to some “acceptable” low level in order
to achieve the greatest possible beneﬁt in terms
of brain lead reduction and hence in terms of
minimizing cognitive dysfunction.
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